Subscribe

Evogene Ltd. (EVGN.TA)

ILA145.80 +7.80 (+5.65%)
IL TLV Healthcare Biotechnology
Address 13 Gad Feinstein Street 7414002
Rehovot, IL
CEO Ofer Haviv
Website evogene.com
IPO 2007-06-13
ISIN IL0011050551

Explore sections of this company profile

Also trades on NASDAQ Global Market · EVGN (USD) Tel Aviv Stock Exchange · EVGN.TA (ILA)
Description

Evogene Ltd. is a computational biology firm specializing in the identification and advancement of products across human health and agricultural sectors. Its proprietary Computational Predictive Biology (CPB) platform leverages deep biological insights, big data, and artificial intelligence to precisely uncover and guide the creation of life science solutions, including novel microbes, small molecules, and genetic components. The company operates through distinct divisions: Agriculture, Human Health, and Industrial Applications. The Agriculture division concentrates on improving crop performance through the development of advanced seed traits, agricultural chemicals, and biological products for crops like corn, soybean, wheat, rice, and cotton. The Human Health division focuses on pioneering microbiome-based treatments for conditions such as immuno-oncology, gastrointestinal ailments, and antibiotic-resistant infections, and also offers medical cannabis products. The Industrial Applications segment is dedicated to developing improved castor bean varieties for various industrial feedstock requirements. Evogene has a global footprint, conducting business in the United States, Israel, Brazil, and other international markets. It maintains significant partnerships, including agricultural collaborations with BASF SE, Corteva, and Bayer, and a medical cannabis development agreement with Cannbit Ltd. through its subsidiary, Canonic Ltd. Established in 1999, Evogene Ltd. is headquartered in Rehovot, Israel.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
ILA145.80 +7.80 (+5.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
59.8K
Beta
0.74
Float Shares
8.63M
Free Float %
99.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.21% +0.00% -14.71% -20.85% -42.37% -30.54% -51.36% -90.98% -98.12% -99.22% -99.98%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (6 ratings, all time) Buy
Price Targets & DCF
Current price
145.80
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-23.64
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -54.7% Q1'26: -86.2% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    +62.0% ★ Q1'26: -60.5% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -418.7% Q1'26: -885.0% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -363.3% Q1'26: -952.1% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    -1,181.2% Q1'26: +415.0% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +35.6% Q1'26: +43.3% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.17× Q1'26: -0.17× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.05) × ERP
WACC = 72% × Ke + 28% × Kd (86.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 145.80
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
11.13M
est: 44.75M (-75.1%)
6.54M
est: 38.09M (-82.8%)
3.38M
est: 11.46M (-70.5%)
1.75M
est: 34.38M (-94.9%)
753.0K
est: 276.32M (-99.7%)
930.0K
est: 1.94M (-52.0%)
1.68M
est: 4.22M (-60.3%)
5.64M
est: 2.51M (+124.8%)
8.51M
est: 10.53M (-19.1%)
3.85M
est: 3.92M (-1.6%)
1.39M
1.39M – 1.39M
-64.4% YoY
2.41M
2.41M – 2.41M
+73.3% YoY
4.59M
4.59M – 4.59M
+90.4% YoY
7.70M
7.70M – 7.70M
+67.7% YoY
13.13M
13.13M – 13.13M
+70.5% YoY
EBITDA
-15.49M
est: -44.75M (+65.4%)
-18.81M
est: -38.09M (+50.6%)
-18.68M
est: -11.46M (-63.1%)
-17.97M
est: -34.38M (+47.7%)
-16.02M
est: -276.32M (+94.2%)
-27.88M
est: -1.94M (-1,338.0%)
-27.01M
est: -4.22M (-539.6%)
-23.26M
est: -2.51M (-827.1%)
-15.48M
est: -10.53M (-47.1%)
-12.85M
est: -3.92M (-228.3%)
-1.39M
-1.39M – -1.39M
+64.4% YoY
-2.41M
-2.41M – -2.41M
-73.3% YoY
-4.59M
-4.59M – -4.59M
-90.4% YoY
-7.70M
-7.70M – -7.70M
-67.7% YoY
-13.13M
-13.13M – -13.13M
-70.5% YoY
EBIT
-17.92M
est: -44.75M (+60.0%)
-21.09M
est: -38.09M (+44.6%)
-20.83M
est: -11.46M (-81.8%)
-20.78M
est: -34.38M (+39.5%)
-18.79M
est: -276.32M (+93.2%)
-30.12M
est: -1.94M (-1,453.2%)
-29.59M
est: -4.22M (-600.7%)
-25.87M
est: -2.51M (-931.2%)
-17.98M
est: -10.53M (-70.9%)
-14.00M
est: -3.92M (-257.5%)
-1.39M
-1.39M – -1.39M
+64.4% YoY
-2.41M
-2.41M – -2.41M
-73.3% YoY
-4.59M
-4.59M – -4.59M
-90.4% YoY
-7.70M
-7.70M – -7.70M
-67.7% YoY
-13.13M
-13.13M – -13.13M
-70.5% YoY
Net Income
-17.21M
est: -42.21M (+59.2%)
-19.59M
est: -38.73M (+49.4%)
-20.84M
est: -44.57M (+53.3%)
-20.76M
est: -46.61M (+55.5%)
-19.12M
est: 54.98M (-134.8%)
-30.45M
est: -41.56M (+26.7%)
-29.84M
est: -45.03M (+33.7%)
-23.88M
-16.49M
est: -32.40M (+49.1%)
-8.48M
est: -4.88M (-73.8%)
-10.96M
-10.96M – -10.96M
-124.6% YoY
-5.85M
-5.85M – -5.85M
+46.7% YoY
-4.02M
-4.02M – -4.02M
+31.2% YoY
-2.92M
-2.92M – -2.92M
+27.3% YoY
-2.19M
-2.19M – -2.19M
+25.0% YoY
SGA
6.35M
est: 247.36M (-97.4%)
5.59M
est: 210.54M (-97.3%)
5.50M
est: 63.33M (-91.3%)
5.60M
est: 190.04M (-97.1%)
5.79M
est: 1.53B (-99.6%)
9.99M
est: 10.72M (-6.8%)
10.42M
est: 23.34M (-55.4%)
9.68M
est: 10.61M (-8.8%)
10.87M
est: 44.53M (-75.6%)
4.62M
est: 16.56M (-72.1%)
5.89M
5.89M – 5.89M
-64.4% YoY
10.21M
10.21M – 10.21M
+73.3% YoY
19.44M
19.44M – 19.44M
+90.4% YoY
32.59M
32.59M – 32.59M
+67.7% YoY
55.56M
55.56M – 55.56M
+70.5% YoY
EPS
-0.68
est: -7.27 (+90.6%)
-0.77
est: -6.67 (+88.5%)
-0.81
est: -7.68 (+89.4%)
-0.81
est: -8.03 (+89.9%)
-0.74
est: 9.47 (-107.8%)
-0.75
est: -7.16 (+89.5%)
-0.72
est: -7.75 (+90.7%)
-0.52
-2.84
est: -4.12 (+31.0%)
-1.08
est: -0.62 (-74.2%)
-1.39
-1.39 – -1.39
-124.6% YoY
-0.74
-0.74 – -0.74
+46.7% YoY
-0.51
-0.51 – -0.51
+31.2% YoY
-0.37
-0.37 – -0.37
+27.3% YoY
-0.28
-0.28 – -0.28
+25.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-26 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-25 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-19 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-18 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-15 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-14 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-13 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-11 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-08 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-01 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-17 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-16 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-18.20M
OE per share TTM
-2.08
Owner's Yield
-89.49%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
124.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-1.2K
Shares Outstanding
8.72M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ofer Haviv Chief Executive Officer, President & Director 423.0K male
Ilia Zhidkov Chief Technology Officer 276.0K —
Yoash Zohar Chief Executive Officer of Casterra Ag Ltd. 251.0K male
Elran Hillel Haber Chief Executive Officer of Biomica Ltd 251.0K —
Amit Noam Capt. res. Chief Executive Officer of Lavie Bio Ltd. 216.0K male
Dan Jacob Gelvan Chief Executive Officer of Ag Plenus Ltd. 210.0K —
Liat Foigel Wejgman Vice President of Human Resources — female
Gabi Tarcic Chief Development Officer — —
Polina Ravzin Chief Financial Officer — female
Russ Putland Executive Vice President Commercial & General Manager USA — male
Yaron Eldad Chief Financial Officer — male
ESG Rating
E (Environmental)
90.9
S (Social)
82.3
G (Governance)
77.1
ESG Total
83.4
ESG Score History
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology